Order Establishes Guidelines for Settlement/Mediation Program for Rhabdomyolosis Claims

MINNEAPOLIS - A Jan. 2 order signed by U.S. District Judge Michael J. Davis establishes the guidelines for the Baycol settlement/mediation program for individuals who developed rhabdomyolosis as a result of using the cholesterol-lowering drug. In re: Baycol Products Liability Litigation, MDL No. 1431 (D. Minn.).

The order describes how claims will proceed through the program, when the settlement amounts will be paid, what will happen to cases that are not settled, and the payment of mediation expenses.

Under the provisions of the program, Bayer has 14 days to decide whether to settle, mediate or deny claims involving documented …